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tObjective: In both the United States and Europe there has been an
increased interest in using comparative effectiveness research of inter-
ventions to inform health policy decisions. Prospective observational
studies will undoubtedly be conducted with increased frequency to
assess the comparative effectiveness of different treatments, including
as a tool for “coverage with evidence development,” “risk-sharing con-
tracting,” or key element in a “learning health-care system.” The prin-
ciple alternatives for comparative effectiveness research include retro-
spective observational studies, prospective observational studies,
randomized clinical trials, and naturalistic (“pragmatic”) randomized
clinical trials. Methods: This report details the recommendations of a
Good Research Practice Task Force on Prospective Observational Stud-
ies for comparative effectiveness research. Key issues discussed in-
clude how to decide when to do a prospective observational study in
light of its advantages and disadvantages with respect to alternatives,
and the report summarizes the challenges and approaches to the ap-
propriate design, analysis, and execution of prospective observational
studies to make them most valuable and relevant to health-care deci-
sion makers. Recommendations: The task force emphasizes the need
for precision and clarity in specifying the key policy questions to be
addressed and that studies should be designed with a goal of drawing
causal inferences whenever possible. If a study is being performed to
support a policy decision, then it should be designed as hypothesis
testing—this requires drafting a protocol as if subjects were to be ran-
ienc
al So
doi:10.1016/j.jval.2011.12.010omized and that investigators clearly state the purpose or main hy-
otheses, define the treatment groups and outcomes, identify all mea-
ured and unmeasured confounders, and specify the primary analyses
nd required sample size. Separate from analytic and statistical ap-
roaches, study design choices may strengthen the ability to address
otential biases and confounding in prospective observational studies.
he use of inception cohorts, new user designs, multiple comparator
roups, matching designs, and assessment of outcomes thought not to
e impacted by the therapies being compared are several strategies
hat should be given strong consideration recognizing that there may
e feasibility constraints. The reasoning behind all study design and an-
lytic choices should be transparent and explained in study protocol. Ex-
cution of prospective observational studies is as important as their de-
ign and analysis in ensuring that results are valuable and relevant,
specially capturing the target population of interest, having reasonably
omplete and nondifferential follow-up. Similar to the concept of the im-
ortance of declaring a prespecified hypothesis, we believe that the cred-
bility of many prospective observational studies would be enhanced by
heir registration on appropriate publicly accessible sites (e.g., clinicaltrials.
gov and encepp.eu) in advance of their execution.
Keywords: comparative effectiveness, prospective observational studies.
Copyright © 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Context and background
In both the United States and Europe there has been an increased
interest in comparative (or relative) effectiveness of interventions
to inform health policy decisions. In the United States, the Amer-
ican Reinvestment and Recovery Act established a federal coordi-
nating council for comparative effectiveness research (CER). This
council defined CER as the “conduct and synthesis of research
comparing the benefits and harms of different interventions and
* Address correspondence to: Marc L. Berger, OptumInsight, Life Sc
USA.
E-mail: Marc.Berger@Optum.com.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.strategies to prevent, diagnose, treat and monitor health condi-
tions in ‘real world’ settings” [1]. It noted that the purpose of this
research is to inform patients, providers, and decision makers,
responding to their expressed needs, about which interventions
are most effective for which patients under specific circum-
stances. To provide this information, CER must assess a com-
prehensive array of health-related outcomes for diverse patient
populations. Interventions may include medications, procedures,
medical and assistive devices and technologies, behavioral
change strategies, and delivery system interventions. Further-
more, it noted that CER necessitates the development, expansion,
es, 301 West 118th Street, Apartment PH 2-C, New York, NY 10026,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
218 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 1 7 – 2 3 0and use of a variety of data sources and methods to assess com-
parative effectiveness.
The American Reinvestment and Recovery Act provided $1.1
billion in funding to the U.S. Secretary of Health and Human Ser-
vices, the National Institutes of Health, and the Agency for Health-
care Research and Quality to promote CER. At the request of Con-
gress, the Institute of Medicine developed a list of 100 priority
topics for CER, most of which involved processes of care rather
than specific therapies. Subsequently, U.S. Health Care Reform
legislation—the Patient Protection and Affordable Care Act—cre-
ated a new entity, the Patient-Centered Outcomes Research Insti-
tute, to identify national research priorities for CER, appoint advi-
sory panels on research design, facilitate public comment, and
disseminate CER findings, as well as to work to improve the sci-
ence and methods of CER through developing and updating stan-
dards on internal validity, generalizability, and timeliness.
In Europe, the European Network for Health Technology As-
sessment initiative was launched in 2006 following the request of
European Union member states in the High Level Group on Health
Services with a work program focusing on a pan-European “core
model” for health technology assessment in Europe, with initial
reports on diagnostics and medical and surgical interventions.
The 2011 European Network for Health Technology Assessment
work program includes research on pharmaceuticals and other tech-
nologies, reflecting a recent focus in Europe on the relative effective-
ness of pharmaceuticals. The Pharmaceutical Forum was developed
in 2005 to bring the European Commission, member states, represen-
tatives of the European Parliament, and a wide range of stakeholders
together to examine challenges relating to providing information to
patients on pharmaceuticals, pricing, reimbursement policy, and rel-
ative effectiveness assessment. In its 2008 report [2], the forum ad-
opted working definitions of efficacy, relative efficacy, effectiveness,
and relative effectiveness. These are shown in Table 1 along with this
task force’s update of the key features.
The report noted that the aim of a relative effectiveness assess-
ment is to compare health-care interventions in practice to clas-
sify them according to their practical additional therapeutic value.
It acknowledged that differences between the objectives and pri-
orities of different national health care systems may create differ-
ences in the way in which health-care interventions will be eval-
uated relative to one another and differences in relative
effectiveness valued. In a survey of 27 member states in 2007,
however, the forum found that little distinction is currently made
in member state assessments between efficacy and effectiveness.
Member states mostly relied on relative efficacy data to inform
their health technology assessments and felt that there was inad-
Table 1 – Categories of intervention effects.
Term Efficacy Relative effic
Definition: Extent
to which
An intervention does more
good than harm under
ideal circumstances
An intervention doe
good than harm,
ideal circumstanc
compared with o
more alternative
interventions
Key features Randomization versus
placebo; select patients;
high-volume centers
Randomization ver
active control; or
indirect comparis
trials versus plac
active comparatoequate effectiveness data available.Generating evidence about new pharmaceuticals, including
biological entities, is increasingly being seen as an activity that
occurs throughout the entire product life cycle rather than pre-
launch for a one-off “at-launch” review. Drug regulatory author-
ities are exploring both early access and provisional access
schemes in which some studies about effectiveness and safety are
conducted postlaunch. Similarly, health technology assessment and
pricing and reimbursement bodies are experimenting with “coverage
with evidence development” including risk sharing that involves col-
lection of additional data postlisting. At the same time, concerns
about safety have led to augmented postlaunch pharmacovigilance
requirements. For most of these initiatives, prospective observa-
tional studies have been the vehicle for evidence collection.
Like pharmaceuticals, medical devices demand scrutiny across
their total life cycle, albeit a life cycle that is typically much shorter
than that of drugs. There is a growing debate about future evi-
dence requirements for medical devices in both the United States
[3] and Europe. Safety and effectiveness evidence for medical de-
vices, along with novel surgical procedures and diagnostics, has
typically involved observational studies.
The ISPOR Board of Directors approved on May 16, 2010, the
formation of the Prospective Observational Clinical Studies Good
Research Practices Task Force to develop good research practices
for prospective observational clinical studies that focus on the
effectiveness and/or comparative effectiveness of health-care in-
terventions. Researchers, experienced in biostatistics and out-
comes research working in academia, government health organi-
zations, contract research organizations, and hospitals from the
United States and the United Kingdom, were invited to join the
Task Force Leadership Group. The task force met about once a
month to develop the topics to be addressed and outlined and to
prepare the first draft report. A face-to-face meeting was held on
March 23, 2011, to debate and finalize any contentious issues in
the draft report. The draft report was presented for comment at
the ISPOR 13th European Congress in Prague, Czech Republic, in
October 2010 and the ISPOR 16th International Meeting in Balti-
more, MD, USA, in May 2011. The draft report was sent for com-
ment to the Task Force Reviewer Group (82 invited and self-se-
lected individuals interested in this topic) on October 12, 2011.
Comments were then considered. The final draft report was sent
for comment to the ISPOR membership via the ISPOR eBulletin
October 2011. Collectively, there were 11 written comments. All
written comments are published at the ISPOR Web site. All com-
ments (many of which are substantive and constructive) were
considered, and once consensus was reached by all authors of the
Effectiveness Relative effectiveness
re
r
An intervention does more good
than harm when provided
under the usual
circumstances of health-care
practice
An intervention does more
good than harm
compared with one or
more intervention
alternatives for
achieving the desired
results when provided
under the usual
circumstances of health-
care practice
f
f
or
Observational study;
heterogeneous patient
population; typical treatment
environment; comparison
typically made to other
treatments
Observational study of
several competing
interventions; or
randomized naturalistic
pragmatic clinical trialacy
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unde
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ne or
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rsarticle, the final report was submitted to Value in Health.
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For the purposes of this report, we apply the following definitions:
Observational Study: A study in which participants are not ran-
domized or otherwise preassigned to an exposure. The choice
of treatments is up to patients and their physicians (subject to
any third-party payer constraints).
Prospective Observational Study: An observational study, often
longitudinal in nature, for which the consequential outcomes
of interest occur after study commencement (including cre-
ation of a study protocol and analysis plan, and study initia-
tion). Patient exposure to any of the interventions being stud-
ied may have been recorded before the study initiation such as
when a prospective observational study uses an existing regis-
try cohort. Exposure may include a pharmaceutical interven-
tion, surgery, medical device, prescription, and decision made
to treat. This contrasts with a retrospective observational
study that employs existing secondary data sources in which
both exposure and outcomes have already occurred.
It is clear that rising requirements for comparative and relative
ffectiveness evidence will lead to an increase in the number of
rospective and retrospective observational studies undertaken
or consideration by health policy decision makers. The ISPOR
ask Force for Good Research Practices for Retrospective Data-
ases Analysis completed its work in 2009 with a focus on CER
4–6]. Our report is focused on setting out good practices in the
esign, conduct, analysis, and reporting of prospective observa-
ional studies that will enhance their value to policymakers. A
umber of issues addressed by the 2009 task force also apply to the
esign and conduct of prospective observational studies, and we
raw on its recommendations, where appropriate. There are,
owever, additional issues that should be addressed when design-
ng a prospective observational study that is “fit-for-purpose” to
rospectively test hypotheses about comparative effectiveness in
atients. For example, patients may be asked to provide responses
o questionnaires that will require appropriate protocol review by
nstitutional/ethical review boards and provisions must be made
o protect confidentiality of patient-identifiable information.
There have been some prior recommendations on the conduct
nd reporting of prospective observational studies. The European
edicines Agency in 2010 drafted a code of conduct to help guar-
ntee high standards, scientific independence, and transparency
n postauthorization safety studies conducted under European
etwork of Centres for Pharmacoepidemiology and Pharmacovigi-
ence (ENCePP) [7]. The ENCePP has itself also created a checklist of
ethodological research standards for ENCePP studies [8]. The
Agency for Healthcare Research and Quality first published a us-
er’s guide describing the appropriate use of patient registries in
2007 [9], focusing on some specific observational study designs
that support CER. In 2008, the International Society for Phar-
macoepidemiology published update guidelines for good phar-
macoepidemiology practices [10]. The STrengthening the Report-
ing of OBservational studies in Epidemiology (STROBE) guidelines
focus on the reporting of observational studies [11]. In our view,
none of the existing recommendations explain or provide general
guidance on how to design a strong prospective observational
study to address comparative effectiveness or relative effective-
ness research questions.
Choice of study design
Potential study designs to assess comparative effectiveness in-
clude retrospective observational studies, prospective observa-
tional studies, randomized clinical trials (RCTs), and naturalistic
(“pragmatic”) RCTs, which we term pragmatic clinical trials (PCTs).
For the purposes of this report, we define a PCT as a randomizedprospective clinical study in which, following randomization to an
intervention, patient care is left to the practitioners according to
their typical practice. PCTs are intended to maintain the advan-
tages of randomization while examining outcomes in routine care
[12]. The definition of what is a PCT, however, falls on a spectrum
[13], and we note that PCTs are not recognized as a separate study
design from RCTs in all jurisdictions. Clinical trialists and others
have questioned whether all effectiveness studies could employ
randomization; therefore, we felt it necessary to address the rela-
tive merits of PCTs compared with those of prospective observa-
tional studies in our report.
Choice of a CER study design follows from the research ques-
tion, but optimal design must consider issues of the expected
value of the information to be generated, clinical equipoise, tim-
ing, feasibility, cost, ethics, and legality. If an observational study
is to assess comparative effectiveness, the first choice to be made
is whether the design should be retrospective or prospective. Ret-
rospective studies are typically performed by using existing data
sets and usually offer advantages in terms of cost and speed of
execution. The data sets, however, may not contain all the infor-
mation desired and therefore definition of exposure and outcomes
may not be ideal. Prospective studies could also use existing data-
bases, but they also offer the opportunity to collect additional de-
sired information, and so they are usually more costly and take
longer to complete. Formal or informal value of information anal-
ysis is useful in making this choice.
When developing an observational study design, it is impor-
tant to consider whether there is clinical equipoise for the treat-
ments of interest and whether the proposed study design and
analysis plan will be sufficient to address confounding and bias.
Clinical equipoise has been defined by Freedman [14] as existence
of “genuine uncertainty within the expert medical community—
not necessarily on the part of the individual investigator—about
the preferred treatment”. Equipoise is defined at both the individ-
ual physician/patient level and the population level [15]. When
true equipoise exists, an observational study will provide good
information to inform comparative effectiveness decisions. Most
situations fall somewhere between true equipoise and clear pref-
erences regarding which treatments should be used in specific
patients (albeit frequently in the absence of good comparative ef-
fectiveness evidence). In the presence of very strong treatment
preferences, observational designs and analytic approaches may
not be adequate to address confounding and bias. In these situa-
tions, a randomized study design may be preferable and one might
explore a naturalistic randomized PCT study design.
When the clinical situation does not involve very strong treat-
ment preferences, either a prospective observational study or a
PCT can be of value and provide useful information. PCTs offer
randomization that may be considered important when the prin-
ciple study question focuses on the relative contributions of dif-
ferent treatments to the observed outcomes. Randomization in
this context provides an additional tool to mitigate concerns about
potential confounding. In PCTs, however, randomization is typi-
cally not enforced and a significant amount of treatment switch-
ing has been observed to occur [16,17] with consequent decrease in
the value of randomization.
Accounting for switching by using various statistical ap-
proaches that are typically applied in observational studies may
enable assessment of the relative contribution of the originally
assigned therapies to the observed relative effectiveness. For dif-
ferent policy questions, such as when the focus is on the relative
outcomes associated with various treatment strategies (that initi-
ate with alternative treatment options), or the relative outcomes
associated with a device versus a drug, observational studies may
be preferred because the extra burdens associated with random-
ization may not be worthwhile. Prospective observational studies
are generally less costly than PCTs and may pose fewer feasibility
220 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 1 7 – 2 3 0issues (including the acceptability of randomization), which factor
into any calculation of the projected value of information.
When prevailing clinical opinion is very strong, neither a pro-
spective observational study nor a PCT may be able to provide
useful information because of confounding. Here, the only option
is to perform a standard RCT of comparative efficacy where treat-
ment assignment is enforced, adherence to treatment is moni-
tored, and switching is not permitted. Such situations most fre-
quently arise when the treatment in question addresses a fatal
condition (Fig. 1). This was the situation in which the efficacy of
high-dose chemotherapy with autologous bone marrow trans-
plantation (HDC-ABMT) as therapy for breast cancer was studied.
The therapy made sense, and there was strong professional inter-
est in offering this option to patients. Indeed, more than 41,000
patients underwent HDC-ABMT for breast cancer and most health
plans provided coverage [18]. In April 2000, the results of a major
randomized controlled trial of HDC-ABMT for the treatment of
metastatic breast cancer showed that there was no survival ad-
vantage to HDC-ABMT relative to standard-dose chemotherapy
[19]. Following these results and similar findings from several
other RCTs, HDC-ABMT fell out of practice.
Typically, there is a relative paucity of head-to-head RCTs that
answer questions of interest to policymakers. On occasion, large
multicenter RCTs such as the Antihypertensive and Lipid-lower-
ing Treatment to Prevent Heart Attack Trial [20] are funded in the
United States by the National Institutes of Health or by the Veter-
ans Administration, and these provide important insights into the
relative outcomes obtained with various treatments. These stud-
ies, however, are very expensive to conduct, take a long time to
complete, and sometimes do not answer questions pertinent to
health policy decision makers when the results become available.
There is little doubt that such trials will provide important infor-
mation in the future; however, it is likely that the number of such
studies that will be conducted is limited. Observational studies
will be an important component of the CER evidence base for the
foreseeable future.
Choice of study design may also be dictated by the technology
being studied. For devices, particularly implants, and for some
biologics interventions, the interventionist’s skill and experience
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Fig. 1 – Consideration of prestudy clinical context and the
size of expected differences in effectiveness are critical to
the choice of study design for comparative effectiveness
research studies. CE, comparative effectiveness; MOD,
moderate; RCT, randomized controlled trial; RE, relative
effectiveness; OS, observational study; PCT, pragmatic
clinical trial; TX, treatment.have important impacts on the safety and effectiveness of theproduct. RCTs are limited in addressing issues of experience be-
cause only elite interventionists are usually recruited. The impact
of the learning curve can be better evaluated in prospective cohort
studies using comprehensive registries with long-term follow-up
[21]. It is often not possible to conduct double or sometimes even
single blinding in implantable device studies and some surgery
studies, particularly when the intervention or device is compared
to nonintervention. Other intervention characteristics also make
blinding difficult. Evaluation of interventions in different delivery
settings, such as in-home as compared with in-hospital, is one
such example. Finally, device development is characterized by fre-
quent modifications of existing products rendering RCTs less use-
ful because by the time the RCT has been reported it is likely that
a new generation of the product is in use in routine clinical prac-
tice. For these reasons, a prospective observational study is a valu-
able design option because it has a shorter timeline.
Sometimes the study goal may involve questions not answer-
able by randomized trials—either standard RCTs or PCTs. The typ-
ical example that comes to mind is that involving the effect of
harmful exposures, such as smoking, where it is clear that ran-
domizing subjects to smoke is unethical. Many other situations
commonly arise in the public health sector. One common example
involves the comparative effectiveness of off-label use of ap-
proved therapies (where an RCT must be performed under an in-
vestigational new drug application). Prospective observational co-
hort studies can provide an opportunity to examine the frequency
and characteristics of off-label use of medical products that occur
as part of the practice of medicine.
Value of information analysis
Value of information analysis is a useful approach to understanding the
trade-offs in selecting different study designs. The objective of this type of
analysis is to understand the value that information from different types
of studies can bring (by reducing the uncertainty as to the benefits of
using a technology) net of the cost of undertaking different types of stud-
ies. This cost includes not only the out-of-pocket costs of the study but also
the delay (in terms of study duration) involved in resolving the uncer-
tainty, which imposes a burden on patients and the health-care system
because more time passes before the results can be used to improve
treatment choices. Typically, retrospective studies are less expensive than
RCTs and take a shorter time to complete. Prospective observational stud-
ies and PCTs fall somewhere in between with respect to out-of-pocket
costs. The quality of the information coming from the study, however, will
also vary, and this needs to be compared with the costs. RCTs typically
reduce uncertaintymore than do other study designs, but take longer, cost
more, and provide information about fewer comparators. Ultimately, the
choice of design for a particular issue will involve trade-offs between
speed, cost, quality, and relevance to key policy questions.
Study Design and Analytical Strategies
Specifying the key policy questions—defining a successful
study
As the study is designed, it is important to revisit the key policy
questions that the study is intended to inform. If these questions
are not answered with sufficient rigor, the study will not be con-
sidered successful. The findings of the study must be judged suf-
ficiently valid to inform the policy decisions faced by decision
makers. While a well-designed study may answer many questions,
there are usually one or two questions that are of greatest interest to
health policy makers. The concept of validity refers to whether a
study is able to accurately answer the questions it is intended to
answer. Validity requires that outcome measurements accurately
reflect the true situations of interest (treatments, health outcomes,
and other characteristics that may influence the likelihood of treat-
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221V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 1 7 – 2 3 0ment success) and that the conclusions drawn from the analysis of
those measurements are well founded. Validity is often character-
ized in terms of “internal validity,” the extent to which a measure-
ment accurately reflects what it is intended to reflect, and “external
validity,” the generalizability of the information to broader settings of
patients, physicians, and health-care settings.
Along with assessing validity, policymakers are assessing
whether the study permits them to draw causal inferences. Causal
inference is a special case of predictive inference where the goal is
to first identify subjects who could have received any of the study
reatments and then infer treatment effectiveness among these
ubjects. From the policy decision maker vantage point, the intent
f CER is to understand which treatments “cause” improvement in
condition and what is the relative improvement caused by vari-
us treatment options. Making any inferences about causal rela-
ionships requires information that is accurate and free from sys-
ematic error. Well-conducted RCTs are generally considered the
gold standard” to establish causal relationships, and it remains a
atter of dispute whether one can ever establish casual relation-
hips in observational studies. It is the position of this task force
hat rigorous well-designed and well-executed observational
tudies can provide evidence of causal relationships.
Specifying the population, comparators, and outcomes of
interest populations
Clear specification of the populations, treatments, and outcomes
of interest is critical to making inferences regarding causal rela-
tionships [22]. The target population of inference can include 1) a
very broad group (assuming what would happen if everyone in a
given population were exposed to a particular policy or not) or 2)
only those who would participate in the policy or only those who
receive a treatment (e.g., effect of treatment on the treated). In the
first situation, if everyone was exposed, the target population is
the whole population, and the causal effect is termed the average
causal effect. Similarly, in a clinical trial setting, if everyone who
was randomized to the experimental treatment complied and ev-
eryone who was randomized to the comparator complied, then
the causal effect is the average causal effect and the target popu-
lation is the population of potential compliers.
There may be more interest in determining the causal effect
among those who would likely receive the treatment (scenario 2).
For example, in assessing the effectiveness of oral antidiabetics, a
policymaker may be interested in determining the effect of treat-
ment among thosewhowould typicallyhave taken the treatment. In
this case, the target population is the population of potential treat-
ment takers. Causal effects of this sort are referred to as the treat-
ment effect on the “treated” and are called local causal effects. Often
patients, clinical decision makers, and payers are interested in
characterizing the effects of treatment in those who actually have
the condition of interest and use the treatment while research-
ers are interested in evaluating broader questions of tolerabil-
ity, adherence, and effectiveness. Potential treatment takers
may include treatment-naive patients and not just those who
have been observed to use the treatment. Similarly, policymak-
ers may be interested in the effect of participation for those who
actually participate in a policy. Subjects who are potential treat-
ment takers are likely to have specific characteristics and needs
that would make them different from a randomly selected sub-
ject.
Finally, in all cases, the target population may consist of sub-
sets of interest, such as the elderly or individuals with specific
characteristics, in which the effectiveness of the intervention may
be thought to vary. In this case, the investigator believes that treat-
ment heterogeneity may exist.
A statement of the primary hypothesis or research question
requires precision and clarity to ensure the design and subsequent
analysis provide meaningful evidence.Treatment heterogeneity
Heterogeneity of treatment effect refers to the fact that individual or
groups of patients experience more (or less) benefit from a treatment
compared with the average effect of the treatment [23,24]. Reasons for
different treatment effects may arise because of biological reasons, pa-
tient or provider preferences, or values.
Interventions and comparators
Determination of the number of treatments and comparators de-
serves careful consideration in designing a prospective study. In
the setting of one treatment (A) and one comparator (B), there is
only one possible comparison, namely, A versus B. When there are
multiple choices available, beyond treatment B, a better strategy
may involve the inclusion of more comparators [22]. Factoring into
this choice will be an understanding of whether various patient
subpopulations are likely to be offered and to receive one or more
of the compared therapies. As the number of treatments in-
creases, however, determination of the causal effects on the target
population becomes more complicated. For example, suppose a
researcher is interested in studying five drugs. In an RCT in which
all patients are eligible for each drug (therefore, the target popu-
lation is everyone), all possible pairwise comparisons could be es-
timated assuming sample size permits. In a prospective observa-
tional study, all patients are not equally likely to receive each of
the drugs even in conditions of apparent clinical equipoise. In-
stead, treatment choices are affected by known and unknown fac-
tors, some of which may be prognostic. As an illustration, consider
when a new asthma treatment is introduced to the market. Gen-
erally, patients who are doing well on their current treatment
would not change to a new drug, especially because new prescrip-
tion drugs are generally more expensive than products that have
been on the market for awhile. Instead, patients who are most
likely to switch to the new drug are those who are sicker or who do
not tolerate treatments currently on the market. A simple study of
outcomes among people treated with the new drug compared
with other marketed treatments may show a lack of effectiveness
of the new drug, in part, because the new users are sicker and
more challenging to cure. Thus, it should be expected that the
characteristics of the treated groups will differ. This is sometimes
referred to as channeling by indication, a type of bias that makes
the analyses more difficult and causal interpretation more chal-
lenging. Even if all factors that impacted treatment choice were
measured, the investigator still must determine which compari-
sons are of primary interest—are all pairwise comparisons impor-
tant or is a comparison of the new drug with each currently mar-
keted drug the focus of the investigation?
Outcomes
In addition to specifying the population and comparators, it is
critical to ensure that the outcomes of interest are specified and
measured. These may include clinical, economic, and humanistic
outcomes; some of this data may be based on patient response to
surveys or questionnaires. For the latter, validation of these out-
comes should be sought by using other means for key clinical and
economic end points if the survey instruments have not been in-
dependently validated. Prospective observational studies also pro-
vide greater potential to examine a broader range of clinically rel-
evant outcomes (e.g., disease flares and readmissions) compared
with retrospective database studies and have a greater opportu-
nity to specify uniform definitions and data collection methods for
both exposure and outcome.
Potential study designs
It is perhaps surprising that there has been little focus in the liter-
ature on designing observational studies to inform health policy
222 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 1 7 – 2 3 0decisions despite its importance. If a study is intended to provide
sufficiently robust information to inform policy decisions, the
study must be designed to test a hypothesis. The task force ad-
opted the assumption that an observational study approximates a
randomized study and thus recommended that a necessary first
step involves drafting a protocol as if subjects were to be random-
ized [25]. This means that investigators should create a formal
study protocol that clearly states the purpose or main hypotheses,
defines the treatment groups and outcomes, identifies confound-
ers (whether measured or not), and specifies the primary analyses
and required sample size.
Choice of a specific design involves balancing the benefits
(the internal validity and external validity of the results) and
costs of the study. Numerous designs for undertaking observa-
tional analyses have been proposed by many researchers across
a variety of research fields. Those developed by epidemiologists
[26] frequently focus on designs to assess the impact of an ex-
posure (most often a drug, medical device, or intervention) or an
outcome (often an adverse event). For CER, the task force fo-
cused on two broad issues— cross-sectional versus longitudinal
designs [27]—and considered only those study designs that uti-
lized at least one comparison group. The comparison group
could be composed of different subjects than those receiving
the intervention or the comparison group could consist of the
same subjects receiving the intervention measured before re-
ceiving the intervention (Table 2).
Single group, pretest/posttest designs
These designs are longitudinal studies in a single group of sub-
jects. The pretest period is defined as the time before the interven-
tion or exposure and the posttest period as the time after the
exposure. Subjects serve as their own control in that outcomes
observed in the posttest period are subtracted from the outcomes
observed in the pretest period for each subject. In the setting of a
single preintervention outcome measurement and a single postin-
tervention measurement, the CER estimate is the average of the
within-subject differences. The main advantage of this design re-
lates to the benefits of using a subject to serve as his or her own
control so that unmeasured time-invariant factors are differenced
out. Disadvantages of single-group pretest/posttest designs in-
Table 2 – Sample designs for prospective observational com
Design Definition
Single group, pretest/posttest
design (also called
interrupted time series)
Outcomes collected before and
for a single group (longitudin
Multiple group, cross-sectional
cohort design
Subjects defined as having a p
who underwent one of mult
interventions/exposures (cro
Multiple group, pretest/posttest
designs (also called quasi-
experimental, difference-in-
difference design; regression
discontinuity design)
Outcomes collected before and
or intervention for at least tw
“intervention” group and a “
group (longitudinal)
Prospective cohort studies Outcomes collected after an ex
or intervention, ideally for a
groups—an intervention gro
comparison groupvolve the lack of a comparison group and the inability to controlfor unmeasured time-varying confounding. The absence of a com-
parison group results in the inability to rule out that changes in the
outcomes would have occurred naturally over time.
If outcomes are collected at multiple time points in the pretest
and the posttest periods, then this design has been referred to as
an interrupted time series design [28]. These designs have often been
utilized to assess policy intervention such as a change in drug
benefit. Interrupted time series are stronger than a single pretest/
posttest design because of their ability to minimize regression to
the mean through collection of repeated measurements. Inter-
rupted time series designs, however, remain vulnerable to time-
varying confounding and to confounding natural history with
treatment effect.
Multiple group, cross-sectional cohort designs
In this setting, outcomes in multiple groups of subjects are com-
pared. The mean outcome in one group is subtracted from the
mean outcome in another group. A key advantage of these designs
includes the ability to quickly measure exposures and outcomes. A
causal effect, however, is difficult to establish unless the investi-
gator has some assurance that the exposure preceded the out-
come and the various treatment groups are comparable along all
the dimensions except the one under study. The lack of longitudi-
nal data makes this design vulnerable to regression-to-the-mean
issues. Moreover, unmeasured differences between treatment
groups may confound the observed treatment effects.
Multiple group, pretest/posttest designs
These longitudinal studies involve multiple groups of subjects in
which the average change in an outcome from baseline for one
group of subjects is compared with the average change from base-
line in another group of subjects. Most often, the average change
in outcome in the exposed group is subtracted from the average
change in outcome in the unexposed or comparison group. For
this reason, these designs have been referred to as difference-in-
difference designs or quasi-experimental designs. The main advantage
of this design is that each subject serves as his or her own control
so that unmeasured subject-specific time-invariant confounders
ative effectiveness research studies.
Advantages/disadvantages
an exposure Subjects serve as own control
Secular trends confounded with introduction
of exposure (subjects or conditions may
change over time naturally)
Vulnerable to time-invariant and time-varying
unmeasured confounding and to confounding
treatment effect with natural history
lar condition
ifferent
ctional)
Vulnerable to time-invariant and time-varying
unmeasured confounding
Vulnerable to regression to the mean
an exposure
oups, e.g., an
arison”
Subjects serve as own control
Disentangle secular trends from intervention
or exposure
Robust to time-invariant unmeasured
confounding
Vulnerable to time-varying unmeasured
confounding
re, diagnosis,
t two
d a
Broad enrollment criteria may enhance ability
to evaluate treatment heterogeneity
Disentangle secular trends from intervention
or exposure
Vulnerable to time-varying unmeasured
confoundingpar
after
al)
articu
iple d
ss-se
after
o gr
comp
posu
t leas
up anare eliminated.
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Like pretest/posttest designs, these longitudinal studies involve
multiple groups of subjects, often starting with first treatment or
diagnosis. Rates of the outcomes of interest are compared, often
using relative risks and risk differences. In contrast to the multiple
groups, cross-sectional design, the use of multiple groups in the
longitudinal setting provides protection against external popula-
tion factors for which confounding effects are relatively constant
across time, for example, time-invariant residual confounding
[29]. These designs, however, are vulnerable to time-varying un-
measured confounding as well as systematic unmeasured differ-
ences in subjects belonging to different groups.
Time-varying and time-invariant confounding
When an outcome and treatment/exposure are both influenced by a third
variable and when the distribution of the third variable is different across
treatment or exposure groups, that variable is called a confounder. Time-
varying confounding refers to the setting in which the outcome and treat-
ment/exposure are influenced by new values of a third variable [30].
Disease severity changes over time, influences the decision to initiate
therapy, and relates to outcome. Time-invariant confounding refers to a
confounder that does not change values over time. For example, a pa-
tient’s socioeconomic status may be related to treatment selection and
functional status, and, assuming a short observational period, does not
change over time.
Addressing confounding and bias in study design
There are many types of bias that should be considered when
designing an observational study but, fortunately, several tools
can be folded into the design to minimize their impact. Major
types of bias include channeling bias (discussed earlier), loss to
follow-up, and misclassification of treatments and outcomes. For
studies of comparative effectiveness, phenomena of episodic use,
complex treatment patterns, and drug switching are examples of
real-world situations that cannot be avoided and must be consid-
ered. Bias can occur in the context of observational studies be-
cause alternative therapies are frequently accompanied by differ-
ing management plans. For example, the selection of monitoring
tests and the frequency of visits are out of the control of the inves-
tigator, especially when some products under study have man-
dated periodic safety tests, such as liver chemistries. Such differ-
ential management may significantly impact patient outcomes
and therefore may confound attempts to understand the relative
contributions of the treatments per se. Capturing a larger number
of providers with variation in their management choices provides
a better opportunity to address this issue.
The choice and the effectiveness of treatments may also be
affected by the practice setting, the health-care environment (e.g.,
single-payer system and fee for service), the experience of health-
care providers, as well as the medical history of patients (i.e., in-
ception cohort vs. chronic users). As an example, it is frequently
the case that the clinicians have strong preferences that may not
be based on evidence but related to their training, health care
system requirements, or individual economic considerations. Re-
searchers may need to conduct some preliminary investigations
to understand these preferences. Another example is that differ-
ent health plans’ formularies may not include all the treatment
alternatives that one wants to compare or they may not place the
alternatives in similar formulary tiers; tier placement is important
because it can encourage or discourage the use of certain prod-
ucts. A third example is that surgeons trained to use newer and
less invasive surgery may apply this technique in their practice
while others are comfortable only with the older procedure. These
situations result in variations in care that can be quite significant
[31]. Identifying and collecting data on these practice patterns canbolster the validity of a large-scale (all inclusive) prospective ob-
servational study.
A related bias results from studying prevalent users, rather
than new users of a given treatment [32]. When prevalent users
are included in a study, it is important to recognize that this study
design will exclude people who are noncompliant, cannot tolerate
the treatment, and many people for whom the treatment did not
work, because those people will no longer be using the treatment.
Study design choices provide important tools for controlling
confounding and various forms of bias by making study groups
more similar [33]. Tools that are often used include inception co-
horts that focus on people with newly diagnosed disease, or may
start when patients first require treatment with medication (e.g.,
first oral antidiabetic [new users]). Incident and new user designs
[32] facilitate drug-drug comparisons for people who are
initiating a pharmacotherapy, combination medications, new
classes of drugs, and so on. This is illustrated by the report of the
re-examination of the Woman’s Health Initiative when observa-
tional hormonal replacement treatment data were analyzed only
for treatment initiators; in this analysis, the results were inferen-
tially the same as for the Woman’s Health Initiative randomized
trial data, which enrolled treatment-naive patients [34]. Earlier
analyses of the Woman’s Health Initiative observational data in-
cluded both currently treated patients and treatment initiators,
causing differences in results from the randomized trial data. The
prior task force on retrospective database analysis has addressed
the incident user design and its alternatives [4].
The goal of these designs is to facilitate comparisons of people
with similar chance of benefiting from the treatment, or experi-
encing harm. For example, a well-described bias can result when
frail elderly people are included in studies, because this popu-
lation is treated differently not simply by virtue of their age but
also because of their infirmity and comorbidities. Differences
may be so extensive that physicians choose not to prescribe
seemingly reasonable treatments for fear of complications or
unknown drug interactions [35]. A more challenging compari-
son presents itself when trying to study medications in compar-
ison to surgery, because the patients considered good surgical
candidates frequently differ significantly from those to whom
medical treatment is offered. Without an extensive, heteroge-
neous pool of comparators to draw from, observational studies
may not be able to address the intractable bias that would result
from such comparison.
The collection of additional outcomes thought not to be im-
pacted by the choice of intervention can bolster findings from ob-
servational studies. These “control” outcomes are outcomes be-
lieved not to be associated with treatment. The task force
recommends the usefulness of such outcomes at study onset with
preplanned collection. If a clinically meaningful difference is ob-
served between treatment and comparison groups for the control
outcomes, then this provides evidence of unmeasured confound-
ing. For example, Mauri and colleagues [36] examined the effec-
tiveness of drug-eluting coronary stents compared with bare
metal stents by using mortality 2 days from stent implant as a
control outcome. Mortality differences between those implanted
with a drug-eluting coronary stent and those implanted with a
bare metal stent at 2 days are not plausible and so, if observed,
would indicate residual confounding.
Similarly, the use of multiple comparison groups can bolster
findings. In some settings, two comparison groups that differ on a
confounder the researcher knows a priori cannot be collected may
still permit some comparisons. For example, in examining the ef-
fectiveness of two drugs, A and B, some subjects may receive drug
B and participate in the registry, while other subjects may not
participate in the registry and also receive drug B. The investigator
may believe that those who participate in a registry are different
from those who do not in terms of compliance and lifestyle. If
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pants, then both cohorts who received drug B could serve as com-
parison groups for drug A. If a similar effect of treatment A com-
pared with treatment B is observed by using either comparison
group, then concern about unmeasured bias due to compliance or
lifestyle is reduced. Yoon et al. [37] used multiple control groups to
xamine the effectiveness of the implementation of the Mental
ealth Parity Act.
Design Tools
Several frequently encountered design problems and potential de-
sign solutions are shown in Table 3.
Managed entry agreements
When there is uncertainty regarding the effectiveness and cost-effec-
tiveness of a new therapy, payers have the option to provide coverage
for them with restrictions. The major strategies applied have included
coverage with evidence development, coverage only in research, and
managed entry agreements including risk-sharing schemes. Managed
entry schemes have been defined as arrangements between manufac-
turers and payers/providers that enable access to (coverage/reim-
bursement of) health technologies subject to specified conditions; these
arrangements can use a variety of mechanisms to address uncertainty
about the performance of technologies or to manage the adoption of
technologies to maximize their effective use, or to limit their budget
impact [38].
In the two well-discussed cases of outcome-based risk-sharing
schemes, the parties opted to create a patient registry or a single-arm
prospective cohort observational study. In the case of bosentan in Aus-
tralia, a registry was established for patients receiving the new treat-
ent, and in the case of treatments for multiple sclerosis in the United
ingdom, a single-arm prospective cohort observational study was
onducted. For both these risk-sharing schemes, the objective was to
se observational data to improve the model-based estimate of the
ncremental cost-effectiveness of the treatments compared with rele-
ant alternatives. The multiple sclerosis scheme has been highly con-
roversial in part because of difficulties with the analysis of effective-
ess [39–41].
It is the view of this task force that these studies should, where pos-
ible, be designed following good practice recommendations for CER. Ide-
lly, studies should either be conducted as prospective observational
tudies using appropriate concurrent comparator groups or be conducted
s PCTs. For the former, patients who do not receive the therapy under
nvestigation would need to be enrolled. In a single-payer system it may
e expected that few patients would be denied the new treatment. In this
ase, a single-arm study would provide information for comparison with
he model-based estimate but understanding of the nature of the historic
ontrol would be needed and the potential for bias would need to be
ecognized.
Other alternatives such as a PCT may also be appropriate. In a PCT,
ne arm may receive a new therapy under the same rigorous set of mon-
toring conditions as in the pivotal RCT and the other armmay receive the
herapy under ordinary practice conditions. This may require that such
Table 3 – Potential solutions for problems frequently encou
Problem
Unmeasured differences in study groups
Differing patient management and monitoring plans
Skill or experience of providertudies be implemented as cluster randomized protocols.It may also be an appropriate alternative to collect evidence on the
comparative effectiveness of the treatment in another jurisdiction where
treatment choices are more mixed. Clearly, issues of the transferability of
results from one area to another would need to be addressed in this
situation. These issues have been addressed by another ISPOR task force
in a reported titled “Transferability of Economic Evaluations across Juris-
dictions: ISPOR Good Research Practices Task Force Report” [42]. We also
note that the ISPOR Performance Based Risk Sharing Task Force is pre-
paring an article on Good Research Practices for risk sharing and related
schemes.
Analytical approaches to address potential bias and
confounding
The analytic approaches and tools recommended by the ISPOR
Task Force on Good Research Practices for Retrospective Database
Analysis to mitigate threats to validity from bias and confounding
in measurement of exposure and outcome apply equally well to
both retrospective and prospective observational studies. Its rec-
ommendations included the need for data analysis plan with
causal diagrams [5], detailed attention to classification bias in def-
inition of exposure and clinical outcome, careful and appropriate
use of restriction, and extreme care to identify and control for
confounding factors, including time-dependent confounding.
This task force (in one of its three articles [6]) also recommended
general analytic techniques and specific best practices including
the use of stratification analysis before multivariable modeling;
multivariable regression including model performance and diag-
nostic testing; propensity scoring; instrumental variables; and
structural modeling techniques including marginal structural
models, as well as rigorous sensitivity analysis. We endorse these
recommendations, and they will not be further discussed in this
report.
One type of bias not discussed by the Retrospective Database
Task Force is immortal time bias. Immortal time is a span of cohort
follow-up during which, because of exposure definition, the out-
come under study could not occur [43]. This can confound the
results of a prospective observational study in two situations:
when the time between cohort entry and date of first exposure is
not accounted for in the analysis and when a decision is made to
switch treatment between the time that treatment is initially
planned and when treatment is actually initiated. In the first sit-
uation, consider the challenge of understanding time to treatment
with prescription medications, where people get sick before com-
ing to medical attention but can be treated only when they come to
attention. People who die before coming to medical attention
would not be included, and effects that occur before coming to
medical attention cannot be studied. For this situation, restriction
or matching methods and time-dependent covariate analyses
have been proposed [44]. For the second situation, intention-to-
treat methodology may be applicable, depending on the research
question.
The analytic plan for a prospective observational study of com-
parative effectiveness should consider issues of treatment com-
plexity (switching, combination, sequencing, dosing, and adher-
ed in the design of prospective observational studies.
Design solution
utcomes not impacted by intervention
ultiple comparison groups (patients, providers, and/or institutions)
ception cohorts
ew user designs
crease number of providers participating in study
tratify sample within provider groups defined by experiencenter
O
M
In
N
Inence/compliance), as may be expected to present themselves in
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ine and anticipate such bias, notably the ENcEPP Methods guid-
ance [45], as well as other documents intended to help readers
evaluate good quality in observational studies of comparative ef-
fectiveness [46].
Addressing treatment heterogeneity in the analytic plan
Most RCTs are underpowered to test for treatment heterogeneity
given such designs effectively require testing for interaction
terms. Post hoc analyses of treatment interactions are vulnerable
to false discovery rates. However, to achieve the goals of CER, rig-
orous methods to estimate treatment heterogeneity will be
needed. Prospective observational studies may be better posi-
tioned to assess treatment heterogeneity given the larger numbers
of subjects that can be accrued. The absence of treatment hetero-
geneity is a crucial assumption for virtually all analytical ap-
proaches including the use of differences in means, propensity
scoring, structural mean models, and instrumental variables.
These analytical approaches as well as standard analyses can ac-
commodate interactions involving baseline modifiers, but not
modifiers that are measured after treatment is selected (e.g.,
changing disease status, comorbidities, or cotreatments).
Intention-to-treat compared with other analyses
The impact of longer follow-up periods with higher dropout and
treatment nonadherence, and switching depends on the pri-
mary planned treatment effect analysis. Intent-to-treat analy-
ses in PCTs estimate the treatment effects that would occur in
populations with similar levels of treatment nonadherence and
switching and are considered useful for policy decisions. As-
treated (on-treated) analyses are more useful in evaluating the
effect of time-varying treatments and switching. Standard as-
treated approaches ignore randomization and remain vulnerable
to unmeasured confounding. Other approaches, such as the “ad-
equate” and “completer” methods, classify subjects according to
randomization but analyze data only for those who receive an
adequate or full amount of the treatment, respectively. All ap-
proaches nonetheless remain vulnerable to unmeasured con-
founding [47] depending on the degree of treatment adherence
and of follow-up.
More rigorous approaches based on instrumental variable
methodology make use of randomization in both RCTs and PCTs
to protect as-treated analyses against unmeasured confound-
ing. Specifically, using the randomization assignment as the
instrumental variable yields a valid estimator of treatment ef-
fectiveness [48]. In this way, PCTs may be superior to observa-
tional studies. This protective property of randomization is re-
duced, however, with longer follow-up and larger magnitudes
of treatment nonadherence, such as treatment discontinuation
and switching, and study dropout. These reduce the advantage
of PCTs over prospective observational studies in practice.
Stated another way, randomization is most protective against
residual confounding with intent-to-treat analyses, but it is less
useful for as-treated analyses, or when there is an expectation
of significant treatment nonadherence. When a prospective ob-
servational study is focused on comparing initial treatment de-
cisions by using intent-to-treat analyses (with propensity
scores or other techniques to adjust for observed factors influ-
encing treatment selection), comparisons among follow-up
treatment decisions or lack of adherence to the initial treatment
decisions (with marginal structural models) may be presented
as as-treated or on-treated analyses [34]. Such an analytic ap-
proach played a role in resolving the conflicting hormonal re-
placement treatment evidence from observational and random-
ized trials. Absence of treatment heterogeneity and no residual
confounding are assumed in these situations unless an instru-mental variable that satisfies the necessary assumptions can be
identified [47].
Sample size calculations
The analytic and design strategies for benefit in terms of relative
effectiveness conflict sometimes with those for risk in terms of
relative safety. In theory, relative effectiveness and relative safety
could be addressed with the same analytical methodology be-
cause the distinction between the safety and effectiveness end
points is artificial—at its simplest, an adverse event is negative
effectiveness. The efficacy comparisons between treatments,
however, can entail either noninferiority or superiority hypothe-
ses (e.g., is drug A equivalent or better than drug B in reducing the
blood pressure). In contrast, the safety assessments are much less
likely to have superiority hypotheses, particularly when the safety
end point is relatively rare. The infrequency of events results in
larger sample size requirements for the assessment of safety and
for assessing superiority as compared with noninferiority. In ad-
dition, the importance of as-treated analyses may be greater for
assessing safety than effectiveness. Thus, for safety assessment,
the role of randomization is limited and given larger sample size
requirements prospective observational studies are more suitable
to address safety concerns, especially in real-world use of a med-
ical technology.
Sample size specification also needs to accommodate issues
of confounding and treatment heterogeneity, but care should be
taken to ensure that a study is not overpowered because enroll-
ment of large numbers of patients without scientific justifica-
tion undermines the study’s scientific credibility and may sug-
gest that study sponsors have primarily a nonscientific agenda,
such as building experience with a new product. There is debate
in general, both for observational and for randomized studies,
about whether effect sizes should come from pilot study data,
the literature, or a general consensus about clinically significant
effect sizes [49]. Estimating effect sizes requires large enough
pilot sample sizes to ensure adequate precision. Obtaining ef-
fect sizes from the literature requires adequate synthesis based
on relevant past studies with enough information for quantita-
tive synthesis methods such as meta-analysis (including mixed
treatment comparisons and network meta-analysis). Ideally,
clinically significant effect sizes should be recognized either
formally as a consensus among clinical researchers and/or so-
cieties of practitioners or informally in the medical literature.
Regardless of how effect sizes are obtained, confounding in-
creases the number of patients required to study because of the
need to identify groups of patients who are similar on the observed
covariates and because of other design considerations (such as the
inclusion of additional comparison groups to bolster the causal
interpretation). Design of PCTs must account for the expectation
of treatment switching and therefore may require larger sample
sizes to provide adequate power to understand the specific contri-
bution of the assigned treatments to outcomes. Expectation of
treatment switching is integral to sample size calculations for pro-
spective observational studies.
Pilot studies or previous studies with a similar focus may
inform the magnitude of confounding by selected observed fac-
tors that can be accounted for in effect size determination. Ad-
ditional information from previous studies include dropout
rates, treatment nonadherence rates (which affect the effect
size), within-subject correlations for longitudinal data analyses,
and within-provider/within-site correlations for studies involv-
ing many providers or sites randomized at the patient, provider,
or site level.
The planned assessment of treatment heterogeneity based on
a priori stratification factors requires sufficient sample sizes for
each combination of factors to facilitate tests of treatment heter-
ogeneity with model-based interactions. For estimation of sample
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gle effect modifier, a general rule of thumb is that roughly a 50%
increase in sample size is required relative to the sample size for
detecting a simple treatment effect [50]. It is important to recog-
nize, however, that even small observational CER studies may pro-
vide important insights, recognizing the limitations described
above.
Study Execution
Given the aim of CER is to inform health policy decisions, the
recommendations of both the ISPOR Retrospective Database Task
Force and GRACE (Good ReseAch for Comparative Effectiveness)
[46] include a requirement for a formal written protocol to specify
the a priori research questions and study design to assure end
users that the results were not the product of data mining. These
recommendations apply to prospective observational studies.
Sample study protocol outline
1. Purpose: What is the key health policy question that the study is
designed to answer?
2. Background: What is the current state of knowledge?
3. Hypotheses:What is the primary hypothesis?What are the secondary
hypotheses (if any)?
4. Study Design:
a. Study design and rationale
b. Definition of population (patients, providers, sites) that will be
studied (target of inference)
c. Definition of treatment cohorts to be compared
d. Definition of outcome measures to assess treatment effects
e. Definition and justification of control outcome (if any)
. Data Analysis Plan:
a. Sample size justification
b. Primary planned analyses, secondary planned analyses
c. Definition of relative effectiveness measure or causal effect (aver-
age causal effect and local causal effect)
d. Planned approaches to deal with bias, confounding, missing data,
and multiple outcomes (if secondary outcomes)
e. List confounders (whether collected or not)
. Study Governance and Implementation:
a. Governance and sponsorship
b. Incentives for participation (if any)
c. Safety reporting
d. Informed consent and institutional review board approval (if re-
quired)
e. Data processing and quality control
f. Sample listing of data elements
g. Plan for dissemination of results and publication planning
h. If the study is designed to support a policy decision, explanation of
decision to register study or not
i. Anticipated timing of dissemination and publication of study
results
trengths of a prospective observational study relate to the ability
ot only to a priori implement common definitions of covariates
nd outcomes but also to collect potential confounders, control
utcomes, and additional comparison groups. Like an RCT, specif-
cs of the study inclusion and exclusion criteria (again, before col-
ection of outcomes) should be listed. Because subjects will not be
andomized to treatments, a list of possible confounders should
e composed and compared with those that are feasible to collect.
rotocols for minimizing missing information should be speci-
ed—these may involve a fixed number of attempts to retrieve the
issing data (e.g., up to five callbacks) or use of proxies wheneasible.If the cost of collecting clinical outcomes on many subjects is
rohibitive or when a large number, relative to the sample size, of
bserved confounders have been selected a priori, the researcher
ould utilize a matched design in which treated and comparison
ubjects are selected through matching or stratification on the
asis of a balancing score, such as the propensity score, and then
ollowed [51]. This would permit more detailed data collection on
smaller sample of subjects. Matched designs provide a mecha-
ism to minimize confounding through the selection of subjects
he researcher believes a priori are similar with the exception of
he treatment received.
Various issues related to study execution can influence the
alidity of the results including selection bias in recruitment of
atients, of health-care providers, and of sites. Because of the in-
reased likelihood of treatment heterogeneity with postmarketing
tudies and the need to assess it, every effort should be made to
omplete studies, even with sample size imbalance across treat-
ent arms. The reason for strengthening the likelihood of study
ompletion in the presence of treatment heterogeneity relates to
he fact that heterogeneity implies more variability, and hence a
arger sample size is needed to preserve power. Moreover, in the
resence of imbalance across treatment arms, the threat of resid-
al confounding due to unmeasured factors such as treatment
references increases. The statistical design and analysis ap-
roaches to account for measured and unmeasured confounders
pply here, unless the imbalances are severe (e.g., SDs of 20% or
arger between treatment groups). In such cases, early termination
ith a futility analysis may then be needed. However, it should be
oted that with such severe imbalances, a futility analysis may
ot be informative.
No matter how good a study concept, protocol, and intentions
f sponsors and collaborators, the details of good fieldwork are the
istinguishing characteristics of successful studies. In observa-
ional studies, the challenges are greater than in RCTs, because the
nvestigators need to work within existing health systems, patient
opulations, and physician groups to conduct exacting science
ithin the constraints of an unruly “real world.” Study manage-
ent and implementation includes issues relating to governance,
ncluding the involvement of expert advisors to provide guidance
advisory boards), questions about appropriate remuneration for
esearchers and subjects/participants, and safety reporting, espe-
ially for studies in which safety may not be the main objective.
tudy samples may be selectively enriched to include the expo-
ures of interest through strategies where enrollment in compar-
tors may be limited so as to be sure that sufficient numbers of
atients with the treatment(s) of interest are recruited for study.
esearchers are further challenged by practical issues including 1)
imiting the length of questionnaires to match the time and pa-
ience of physicians and patients who rarely receive much, if any,
ompensation for their cooperation and 2) managing to collect the
ata of interest within regularly scheduled encounters with
ealth-care providers. Other challenges include addressing issues
f missing data and data quality, because prospective observa-
ional studies have traditionally channeled any additional re-
ources into recruiting larger numbers of patients and into longer
ollow-up, rather than into source data verification, which is a
arity for most of these studies. Other questions of interest related
o reporting and publication include whether observational stud-
es should be registered and how to work with coauthors on pub-
ications such that they ethically can attest that they have partic-
pated in data analysis and whether this requires providing all
oauthors with copies of the data sets, and if and when data access
hould be granted to nonparticipating investigators.
Good governance
Advisory boards can be useful to promote avoidance of conflicts of
interest and appropriate study execution and reporting. Large ob-
227V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 1 7 – 2 3 0servational clinical studies often include scientific advisory boards
comprising clinician disease experts, statisticians, and epidemiol-
ogists. While the role of advisory boards varies from project to
project, these boards can provide ongoing guidance about opera-
tional issues that may influence validity. For example, sequential
enrollment plans may not always be feasible and investigators
may propose alternatives that require scrutiny in terms of protec-
tion from bias. The most successful advisory boards have written
charters that lay out their roles and responsibilities, including
rules for voting at formal meetings and in special situations that
may arise between meetings.
Incentives for participation
Institutional/ethical review boards are appropriately sensitive to
the threat of coercion that can stem from excessive compensation
for participation in research. Payment to health-care providers, if
any, should be commensurate with work performed. In some in-
stances, it may be acceptable to provide a modest bonus for com-
pletion of a long-term study or for studies that involve low-risk
procedures (such as endoscopy, multiple blood samples for phar-
macokinetic studies, and gynecological examinations). Patients
are sometimes offered gift cards; once again, the value of the gift
should be related to the length of time and effort required to par-
ticipate in the study.
Some studies do not offer any payment to health-care provid-
ers for time spent preparing and submitting data for a study. In-
complete reporting, however, is more common when there are no
payments or other incentives for participation. Payments are of-
ten made per patient visit, rather than using an annual payment
system. This payment strategy provides a more proximate incen-
tive to complete case report forms and may be more effective at
ensuring data collection.
Is it worth “registering” an observational study?
Similar to the concept of the importance of declaring a prespeci-
fied hypothesis, some feel that validity is enhanced by registering
studies in advance of their execution. Many groups register their
studies on clinicaltrials.gov, although there is no mandate or re-
quirement for that reporting. The Agency for Healthcare Research
and Quality in the United States has recently initiated a contract
for the development of a registry of patient registries in the United
States; recommendations are under development. In Europe, the
ENcEPP recently created a voluntary registry for observational
pharmacoepidemiology and pharmacovigilance studies, and it
has instructed that any study that wishes to receive the ENcEPP
Seal of Approval be registered before it commences. The ENcEPP
program also requires that the protocol be provided and pro-
vides a mechanism for the protocol to be kept confidential for
some period of time. For CER, registration of prospective obser-
vational studies will enhance their credibility with key decision
makers and we encourage researchers to register their studies.
Data access
Routinely, the editors of scientific journals ask authors to sign a
statement declaring that they had full access to all study data used
in the development of the article. “Full access” to study data, how-
ever, is not defined. In major RCTs, some funding agencies and
journal editors have required that authors include a statement in
the published article that readers may contact the first author to
request access to the full study data set (e.g., Hull et al. [52]). While
the rationale for the Food and Drug Administration requirement
that a pharmaceutical company supply the raw data used in its
analysis of clinical trials to Food and Drug Administration statis-
ticians in support of a new drug application is compelling [53], the
appropriate balance of interests in access to raw study data be-
tween study sponsors, journal editors, and interested individualswho wish to conduct an independent examination of raw study
data is less clear for observational clinical studies.
In general, proprietary observational disease registries have
not routinely shared their raw data with investigators outside of
the study coordinating center team. This caution in allowing broad
access to data reflects scientific, ethical concerns about data own-
ership, patient privacy, and contractual obligations to sponsors,
physicians, and hospitals, who have agreed to share their patients’
data in a proscribed, limited manner. However, a number of ob-
servational clinical registries have developed written publication
guidelines for data access and approval of publication topics and
authorship, which at least clarify how interested parties may ap-
proach investigators for collaborative research, if not providing
direct access to the data of interest (e.g., The Global Registry of
Acute Coronary Events [54], Coronary Artery Risk Development in
Young Adults [55], The Global Longitudinal Study of Osteoporosis
in Women [56], and Can Rapid Risk Stratification of Unstable An-
gina Patients Suppress Adverse Outcomes With Early Implemen-
tation of the ACC/AHA Guidelines [57].) A number of limited data
sets have been shared with bona fide investigators from outside
the scientific advisory boards of these studies [58]. Furthermore,
federally sponsored multicenter data sets often include a manda-
tory requirement allowing individuals unrelated to the leadership
of the study to request access to all or major portions of the raw
study data [59]. Also, some journal editors have taken the position
that study data should be made available to others, for example,
the British Medical Journal [60], provided that such release has been
guaranteed in the patient informed consent, and, we would add, in
the agreements with participating investigators.
Most often, however, authors of scientific articles that examine
data from industry-sponsored multicenter voluntary observa-
tional clinical databases, for which the data are held and analysis
is performed by a central study coordinating center (e.g., a univer-
sity or contract research organization), have limited access to the
raw study data. They have received summary data and appropri-
ate statistical findings for all the questions they have proposed in
preparing the manuscript for submission to a scientific journal. In
this model, the coordinating center conducts the analysis and pro-
vides collaborating authors with copies of analytic tables and fig-
ures during the course of analysis and writing. For observational
studies of comparative effectiveness that use de novo data collec-
tion, this practice is preferred for both practical and professional
reasons. The investigators who created and operate the study
have the best understanding of the data definitions and the cir-
cumstances under which they were collected. Thus, the absence
of a critical data element may be interpreted differently according
to how the data were collected. For example, in claims data a
missing element may indicate that a test was not done; yet de-
pending on the nature of the data source, it may also reflect that
those tests are not covered by the health insurance provider
that provided the data for the study. In other situations, missing
treatment data more likely may be assumed to indicate no
such treatment, such as when data are obtained through chart
abstraction [61].
Safety reporting
Operational issues may occur because of safety reporting obligations
of funding sources. In this situation, selective recording of reportable
adverse events and serious adverse events should be conducted uni-
formly across all comparators, and not simply for the products for
which the funders have market authorization [62].
Reporting Study Findings
Reporting should be in line with good practice in pharmacoepide-
miology studies and retrospective database analysis and not spe-
g
E
t
a
h
c
i
●
●
●
●
●
●
●
●
228 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 1 7 – 2 3 0cific to prospective observational studies [4–6,9,63]. We also note
that Consolidated Standards of Reporting Trials can be useful for
the reporting of nonrandomized studies [64] while the STROBE
uidelines [11] and the Meta-analysis Of Observational Studies in
pidemiology guidelines [65] are designed specifically for observa-
ional studies. Reporting should be consistent in a way that en-
bles it to be used in meta-analysis [66]. To this end, some journals
ave required that a “Reproducible Research Statement” be in-
luded in the article [67]. Thus, specific reporting features should
nclude the following:
A clear statement of the study question
Outline of the research design (and the reasons for choice of
design) and methods (source population, target population,
selection of subjects, data collection methods, statistical
methods)
Sources of data
Any circumstances that may have affected the quality and in-
tegrity of the data
Analysis including adjustments for confounding
Results including quantitative estimates of effect, confidence
intervals, and sensitivity analyses
Statement of conclusions and implications
Reproducibility research statement
Interpretation
The GRACE principles set out a set of principles that can help in
recognizing high-quality observational studies of comparative ef-
fectiveness. The three key principles are as follows:
● Were the study plans specified before conducting the study,
including the outcomes and comparisons?
● Was the study conducted consistent with good practice and
reported in sufficient detail for evaluation and replication?
● How valid was the interpretation of the results for the popula-
tion of interest?
The key challenge in the interpretation of prospective observa-
tional studies is the potential for confounding. How much could
unmeasured confounders have influenced the results? Unmea-
sured confounding is much more likely to explain small effects
(odds ratios) than large ones. Beyond using statistical techniques,
as discussed above, there may be other ways to improve confi-
dence in the results. For example, are there other studies in this
subpopulation and for any of the treatment comparators? Consis-
tency of findings would enhance the validity of the findings. If
there are RCTs conducted on the same comparators, then confi-
dence in the study results (lack of confounding) can be improved if
the results for the relevant subgroups of the prospective observa-
tional study match those of the RCT [4,68]).
Interpretation may also need to take account of the funding
source for the study and authors’ right to participate in the study
design, select hypotheses, pose queries on the data, and exercise
editorial control over the final publication.
Recommendations and Conclusions
Prospective observational studies will undoubtedly be conducted
with increased frequency to assess the comparative effectiveness
of different treatments, whether as part of the overall increase in
interest and funding for CER or as a tool for “coverage with evi-
dence development,” “risk-sharing contracting,” or key element in
a “learning health-care system.” This report summarizes the chal-
lenges and approaches to the appropriate design, analysis, and
execution of prospective observational studies to make them mostvaluable and relevant to health-care decision makers. Some of the
important points made in this report include the following:
● Precision and clarity in specifying the key policy questions to
be addressed is paramount, and studies should be designed
with a goal of drawing causal inferences whenever possible.
● If a prospective observational CER study is being performed to
support a policy decision, then it should be designed to test a
hypothesis—the protocol should clearly state the main hy-
pothesis (or research questions), define the treatment groups
and outcomes, identify measured and unmeasured confound-
ers, and specify the primary analyses and required sample size.
● Careful consideration should be taken in choosing to perform a
prospective observational study over alternative CER designs:
retrospective observational studies, rigorous randomized con-
trolled clinical trials, and PCTs. Researchers should provide
their rationale for opting for a prospective observational study
and discuss critical issues such as the nature of the key re-
search question, feasibility, value of information (likelihood
and value of answering the question vs timeliness and cost),
and any specific considerations with respect to the technology
(e.g., devices and procedures) being evaluated.
● Separate from analytic and statistical approaches, study design
choices may strengthen the ability to address potential biases
and confounding in prospective observational studies. The use
of inception cohorts, new user designs, multiple comparator
groups, matching designs, and assessment of outcomes
thought not to be impacted by the therapies being compared
are several strategies that should be given strong consideration
recognizing that there may be feasibility constraints.
● The reasoning behind all study design and analytic choices
should be transparent and explained in the study protocol.
● Execution of prospective observational studies is as important
as their design and analysis in ensuring that results are valu-
able and relevant, especially capturing the target population of
interest, having reasonably complete and nondifferential fol-
low-up.
● We believe that similar to the concept of the importance of
declaring a prespecified hypothesis, the credibility of many
prospective observational studies intended to be used for deci-
sion support would be enhanced by their registration on ap-
propriate publicly accessible sites (e.g., clinicaltrials.gov and
encepp.eu) in advance of their execution.
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